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Abstract

Results: In 2014, DC Medicaid spent more than $17.1 million on pharmaceutical
treatments for diabetes. We estimated that ten companies spent $3.8 million in
detailing expenses to market diabetes drugs in 2014. SGLT-2 inhibitors and GLP-1
analogues had the highest estimated detailing expenses, each totaling more
than $1.2 million. From 2014 to 2015, DC Medicaid spending for Victoza
(liraglutide), a GLP-1 analogue, increased 51% (from $183,873 to $362,230) and
Invokana (canagliflozin), a SGLT-2 inhibitor, increased 213% (from $8,933 to
$27,958).
Conclusions: Pharmaceutical promotion drives unnecessary use of newer, more
expensive medications. The District of Columbia should provide education on
rational prescribing for diabetes treatment (including diet and exercise).
Funding for this research came from the District of Columbia Department of
Health, Health Regulation and Licensing Administration.
More information about pharmaceutical marketing in DC can be found at
https://doh.dc.gov/service/prescription-drug-marketing-costs-access-rx

In 2014, pharmaceutical and device manufacturers reported a total of
$91.1 million for gift, advertising, and aggregate (detailing) expenses in
the District of Columbia.5

The District of Columbia Medicaid prescription drug program cost $153 million in 2014, of which
Medicaid reimbursed $151.9 million. Drugs to treat diabetes made up more than 10% of all DC
Medicaid drug spending. Between 2010 and 2014, DC Medicaid spending on diabetes drugs
jumped 350% from $3.7 million to $17.1 million.4

We identified 50 diabetes drugs (42 branded and 8 generic drugs).
According to data from Open Payments, physicians accepted more than
$360,000 worth of gifts related to diabetes medication from
pharmaceutical and device manufacturers.

Cost of Diabetes Drugs to DC Medicaid and Number of DC Diabetes Cases
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GLP-1 analogues and SGLT-2 inhibitors are both relatively new classes of diabetes drugs, and both
classes had relatively low numbers of prescriptions reimbursed by DC Medicaid in 2014. GLP-1
analogues had the highest costs per prescription, ranging from $404 - $489. SGLT-2 inhibitors also
had high costs per prescriptions, ranging from $271 - $303. These newer drug classes show modest
benefits but are far more expensive than the older, more efficacious diabetes drug metformin.2

Attributed Detailing Formula

Estimating Diabetes Detailing Expenses
To estimate the amount spent on detailing for each diabetes drug, we developed a methodology to combine
information from Open Payments and AccessRx. Drugs were grouped by class in order to maintain the
confidentiality of proprietary data. The attributed aggregate detailing amount could be a marker for how extensively
specific drugs are being marketed in the District.

Summary of Attributed Detailing
Number of
Companies

Estimated Attributed
Aggregate Detailing
Expenditures

GLP-1 analogues

4

$1,295,681

SGLT-2 inhibitors

4

$1,227,029

DPP-4 inhibitors

5

$635,773

Insulin analogues

3

$523,936

DPP-4 inhibitor
combinations

4

$72,968

Class of Drug
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Invokana (canagliflozin), a SGLT-2 inhibitor, was the diabetes drug with
the most associated payments with $154,000. Bydureon (exenatide) and
Victoza (liraglutide), both GLP-1 analogues, were associated with gifts to
physicians totaling $65,191 and $44,659 respectively.
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NUMBER OF DIABETES CASES IN DC

Methods: The AccessRx program in DC requires pharmaceutical companies to
report gifts given to healthcare providers, drug advertising expenses, and the
salaries for staff engaged in promotional activities (“detailing expenses”). We
combined data from AccessRx and the federal Open Payments system to
estimate promotional payments. We used Medicaid drug utilization data to
examine spending for diabetes treatment.

In 2014, one in eleven (9.1%) of DC residents had diabetes. Diabetes was the ninth leading cause
of hospitalization in DC, with 1,572 visits. Diabetes was the fifth leading cause of death in DC,
killing more people than lower respiratory diseases, Alzheimer’s disease, HIV/AIDS, or homicides.3

COST OF DIABETES DRUGS TO DC MEDCAID

Background: Growth in pharmaceutical expenditures for diabetes outpaced
growth in diabetes prevalence. Prescribers accepting gifts and meals from
pharmaceutical companies have been linked with higher prescription rates and
costs.1 Pharmaceutical marketing to these prescribers and patients often
promotes newer, more expensive drugs, such as the GLP-1 analogues and SGL-2
inhibitors. These two drug classes are more expensive but no more effective
than metformin, the recommended first-line treatment for diabetes, and the
oldest and cheapest available treatment. 2 We investigated how cost of diabetes
treatment was affected by marketing practices in the District of Columbia.

Promotion of Diabetes Drugs
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We estimate that these ten companies spent about $3.8 million in salary for sales staff to promote diabetes drugs in
the District of Columbia. The newly approved SGLT-2 inhibitor and GLP-1 analogue drug classes had the highest
estimated detailing amounts, totaling more than $1.2 million each. We predicted that high expenditures for
promoting these classes in 2014 would precede an increase in the number of prescriptions reimbursed by DC
Medicaid for these two classes of antidiabetics in 2015.
As follow-up to this analysis, we found that spending for some SGLT-2 inhibitors and GLP-1 analogues had increased.
From 2014 to 2015, DC Medicaid spending for Victoza (liraglutide), a GLP-1 analogue, increased 51% (from $183,873
to $362,230) and Invokana (canagliflozin), a SGLT-2 inhibitor, increased 213% (from $8,933 to $27,958).

While our research shows some connection between marketing and increased public expenditures on drugs, further
research into the effects of pharmaceutical marketing on prescribing choices and its effect on public programs like
Medicaid is needed.

